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An alarming rise in overweight and obesity was observed worldwide, particularly
during the 1990’s, in both the developed and developing countries. Obesity is a
serious health risk; it is a major determinant of different diseases such as diabetes
mellitus, hypertension, heart and kidney failure, atherosclerosis, cancer, infertility,
birth complications and arthritis.
On the other hand, obesity is largely preventable through changes in lifestyle. The
prevalence of childhood obesity continues to increase at a rapid rate. In the United
States the National Health and Nutrition Examination Survey IV (1) showed that 13-
14 % of children aged 6-11 years (yr) and adolescents aged 12-19 yr were
overweight, while data from 1999-2000 indicated continued increases to 15.3 % of 6-
to 11-yr-olds and 15.5 % of 12-to 19-yr-olds (2). In three cross-sectional studies of
England and Scotland in 1974, 1984, 1994, only minor changes were found in the
prevalence of overweight or obesity between 1974-84, but by 1994, the prevalence
had risen by 9-10 % in boys, to over 13 % of English girls and to nearly 16 % in
Scottish girls (3). Similar trends have been seen in other developed and developing
countries. In Hungary, the prevalence of obesity increased from 12% to 16 %
between 1980’ and 1990’s among schoolchildren (4).
Obesity is a heterogeneous group of conditions with multiple causes. Body weight is
determined by an interaction between genetic, environmental and psychosocial
factors. Although genetic differences are of great importance, the marked rise in the
prevalence of obesity is best explained by behavioural and environmental changes.
Identical twins of obese parents are more likely to become obese than those of non-
obese parents, suggesting a genetic factor to obesity. In a review on twin, adoption
and family studies, body mass index (BMI) inheritance has been proposed to account
for 25 % to 40% of the inter-individual variability (5).
Obesity is one of the features accompanying numerous genetic syndromes, like
Prader-Willi (PWS), Cohen, Alstrom and Bardet-Biedl syndrome that have been
genetically mapped (6). The first gene identification in obese human subjects was
linked with the screening for genes identified previously in rodent models of
monogenic obesity. These rodent models mostly involved genes in the regulatory
pathway of food intake, which is mostly similar in human monogenic obesity (7).
However, the genetic susceptibility to obesity is in most cases polygenic, and is
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rarely the result of a Mendelian gene (monogenic obesity). Apart from rare obesity-
associated syndromes, the genetic influences seem to operate through susceptibility
genes. Such genes increase the risk of developing a characteristic but are not
essential for its expression or, by themselves, sufficient to explain the development
of a disease. The susceptible-gene hypothesis is supported by twin studies in which
pairs of twins were exposed to periods of positive and negative energy balance, and
the differences, for example, in the rate and the proportion of weight gain showed
greater similarity within pairs than between pairs (8), which can suggest differences
in genetic susceptibility within a population. One of the two approaches to identify
susceptibility genes is the candidate gene approach. It involves testing the association
between obesity and a specific allele of a gene either in a family study or in a large
cohort of unrelated controls and patients. Several candidate genes have been
associated with human obesity and its metabolic complications, which include e.g.
receptors that are important in thermogenesis (β3-adrenergic receptor /3-BAR / gene
and the family of uncoupling proteins), as well as those involved in appetite
regulation.
The effects of catecholamines are modulated through four subtypes of
adrenoreceptors (9). The human 3-BAR is expressed predominantly in visceral fats,
where it plays a role in determing the resting metabolic rate through its ability to
stimulate lipolysis and thermogenesis (10). The involvement of 3-BAR in energy
metabolism originates from observations indicating the prevalence of the genetic
variant at the codon 64 of the 3-BAR gene leads to replacement of a tryptophan with
an arginine (Trp64Arg). This polymorphism has been reported to be associated with
abdominal obesity (11), a propensity for weight gain (12), high BMI (13,14), insulin
resistance (11,14) and an earlier onset of type 2 diabetes mellitus (11, 15). Other
studies, however, could not demonstrate these associations (16,17).
An obese child will remain obese in adulthood and become at risk for acquiring or
increasing coronary heart disease in 30 % to 60 % of cases (18). Although genetics
may have a part of it, several environmental factors affect this phenomenon
significantly. The first contact of the child with the environment is in the uterus.
Over- or under-feeding in pregnancy has been associated with the development of
obesity in later life (19,20). Beside of the prenatal period, the other critical period is
the adolescence in the development and persistence of overweight in the paediatric
age group. The period of ’adiposity rebound’ may constitute a third. It is when the
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BMI begins to increase after reaching a nadir in early childhood. After birth the
method of feeding may influence the risk of obesity. Family lifestyle and food habits
play a role in children’s food preferences and physical activity which may affect their
body weight. Small for gestational age (SGA) has been associated with increased
risk of diseases such as diabetes or cardiovascular disease in adulthood
(21,22,23,24). Infants with high birth weights appear to have an increased risk of
subsequent overweight (20).
The presence of inherited and acquired thrombophilias has recently been linked to
most cases of maternal venous thrombotic events as well as these adverse obstetric
outcomes (25). One of the most common inherited thrombophilias is heterozygosity
for the factor V Leiden mutation. Although there is no consensus on the association
between the factor V Leiden mutation and early pregnancy loss, but the evidence
suggests an association between the mutation and late (first-, second-, third-
trimester) fetal loss, severe preeclampsia, abruption and severe intrauterine growth
retardation (IUGR) (26,27,28,29,30).
Over the past two decades, many papers have demonstrated that low birth-weight,
thinness and short body length at birth are associated with increased risk of
atherosclerosis, type 2 diabetes mellitus (T2DM), hypertension and metabolic
syndrome. This observation, which originated at Hertfordshire in the United
Kingdom (21,22,31) was confirmed in other countries such as Sweden (32) and
Netherlands (33). The association of low birth-weight with adult cardiovascular
disease led to the ’fetal origins or thrifty phenotype hypothesis’ formulated by Barker
(34). According to this hypothesis, an impaired intrauterine milieu, such as nutrient
restriction , causes a ’reprogramming’ of the endocrine-metabolic status of the fetus,
which has short-term survival benefits, but this reprogramming can be detrimental
effects on long term. If the prenatal nutrient restriction is subsequently followed by
an extrauterine nutrient abundance, the risk of the development of metabolic
syndrome increases, because this reprogramming consist mainly of the development
of insulin resistance (23,35,36,37). There are, however contradictory results
(38,39,40). Many researchers dispute the ’fetal origins hypothesis’, asserting that
environmental (e.g. maternal smoking, drug abuse, abnormal BMI etc) and genetic
factors can, at least in part, explain the association between SGA and adult
cardiovascular risk (41,42). Several pathophysiological mechanism are implicated,
but in addition to the intrauterine retardation the sudden break of fetal development
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and the accelerated pace of postnatal ’catch-up’ growth might also play a role in the
pathogenesis of these chronic diseases (23,42,43,44,45,46).
Obese children have a higher prevalence of T2DM and insulin resistance (47,48,50)
and the frequency of this complication appears to have risen in recent years
paralleling the worldwide increase in obesity in this age group. On the basis of the
available data, the prevalence of T2DM in Caucasian children and adolescents
(49,50,51,52) seems to be much lower then those reported in other races (53,54), but
more representative, population-based surveys are needed. Although the presence of
impaired glucose tolerance and chemical diabetes in obese children has been reported
as early as the 60s, 70s of the last century (55,56,57), but it has become a hot topic
only recently. Sinha et al. (58), in a multiethnic cohort of 167 obese children and
adolescents demonstrated abnormal glucose tolerance in 25 % of children and 21 %
of adolescents. According to the European literature, the first case of childhood
T2DM in Europe was diagnosed in 1993 (59). Only two population-based reports
have been published, by Rami et al. from Austria (60) and Ehtisham et al. from the
UK (61). In April 2002, a questionnaire was distributed among European Childhood
Obesity Group (ECOG) representatives from 16 European countries, which included
several questions concerning the prevalence, risk factors and complications of
childhood obesity, such as T2DM. From nine countries, altogether 184 European
children were diagnosed with T2DM, 144 of them of Caucasian origin. The majority
of them were overweight females and had positive family history for T2DM (62).
Though both genetic and environmental factors play a role in the pathophysiology of
T2DM, its rapidly increasing rates cannot be attributed to an altered genetic pool but
rather to the raising prevalence of obesity.
Although general principles of treatment of T2DM in adolescents are similar to the
treatment of adults there is general agreement between the paediatricians dealing
with this problem that they should not be a simple extrapolation (50, 63, 64).
Treatment strategies should be based on symptoms at presentation. Asymptomatic
children identified at routine testing should be counselled on the necessary lifestyle
changes. Therapeutic strategies include lifestyle and behaviour modification,
nutrition education, and psychological and family therapy interventions. Because
obesity is the major problem in most adolescents with T2DM, dietetic advice is
mandatory, although calorie intake should not be too restricted to ensure normal
growth and pubertal development. Patients should be encouraged to increase their
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physical activity or at least to decrease inactivity. However, if the treatment goals
are not achieved, pharmacological therapy should be considered. Recently,
metformin has been approved by Food and Drug Administration (FDA) for use in
children, and has been recommended by the American Diabetes Association (ADA)
as a first line oral agent for treatment of T2DM in children (65,66). In symptomatic
youth, particularly if ketonaemia develops, insulin treatment should be initiated to
achieve good glycaemia control.
Childhood onset of adult cardiovascular disease has become a significant public
health problem that needs to be addressed globally and individually. Whether
genetic, environmental, or fetal influences are the primary culprits in the epidemic of
obesity-related adult cardiovascular diseases seen today remains unknown. In spite of
this, the interventional focus should be placed on early life, and health care providers
and public health professionals should pay attention to the elevated future coronary
heart disease risk among children. Better understanding of the aetiology of these




1. Trp64Arg polymorphism of the 3-adrenergic receptor gene
1.1 To examine the frequency of Arg64 allele of the 3-adrenergic receptor (3-BAR)
gene, which is one of the known candidate genes, in healthy and obese Hungarian
children.
1.2 To look for possible associations between this polymorphism and some clinical
and metabolic characteristics of obese children.
2. Leiden mutation; size at birth and later risk factors
2.1 To test the prevalence of Leiden mutation in the mothers of premature infants and
in the mothers of intrauterine-growth-retarded children.
2.2 To determine the association between size at birth and later risk factors
(hypertension, hyperinsulinism, hyperglycaemia, dyslipidaemia) in prepubertal
children.
3. Impaired glucose tolerance and type 2 diabetes mellitus
3.1 To examine the prevalence of impaired glucose tolerance (IGT) and T2DM in
obese Hungarian children.




Written informed consents were obtained from the subjects and all parents of the
children before enrollment in the different studies. All of the studies were approved
by the ethic review committee of the University of Pécs.
1.1 In all, 295 obese children (male:168) were included in the study after the
exclusion of any endocrinological disorder, nutritional-, growth- and renal problems
or obesity syndromes. With the exception of obesity, the children had no apparent
disease and were not taking any kind of medication. A total of 147 healthy, non-
obese children (male: 68) recruited from elementary schools, served as controls. The
average age of the children in the two groups was 12.63.2 and 12.41.7,
respectively.
1.2 Obese children carrying the Arg64 allele (n=35, male: 23) were compared to
randomly chosen, obese children without the Arg64 allele (n=35, male: 20).
2.1 White (Caucasian) mothers of premature (Group PM; n=50) and mothers of
intrauterine growth retarded neonates (Group IUGR; n=56) were tested. The
newborns were considered as premature when their gestational age was < 37 weeks.
Intrauterine growth retarded children were born full term with birth weight, height
and head circumference below the 10th centile (proportional) or with birth weight
below the 10th centile, but with normal length and head circumference
(disproportional).
2.2 229 children (134 boys, 95 girls) were examined at the age of 6-10. We
compared children born full term with normal weight, height and head circumference
(1st group), the children born full term with birth weight, height and head
circumference less than 10th centile (2nd group), children born full term with birth
weight less than 10th centile and with normal length and head circumference (3rd
group) and children who were preterm at birth (4th group) according to the criteria
by Fekete et al (67). The age of children at the time of investigation was comparable
in the four groups.
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3.1-2 Oral glucose tolerance test (OGTT) was performed in 289 obese (153 boys)
(mean BMI±SD: 31.14.6 kg/m2) adolescents (mean age±SD, 12.92.7 years). After




These investigations included weight, height and skin-fold thicknesses. Weight was
obtained with subjects wearing light clothing to the nearest 0.1 kg on a standard
beam scale. Height was measured to the nearest 0.1 cm by a Holtain stadiometer. In
all examinations, children were considered as obese if their body weight exceeded
the expected weight for height with more than 20%, and if body fat content with
more than 25% in males and 30% in females. BMI was calculated according to the
formula, real weight (kg)/height2(m2), while body fat (BF) was estimated from
skinfold measurements, which were performed with a Holtain caliper, using
Parizkova and Roth’s formula (68). The body weight of control, healthy children was
less than 120% of the expected weight for height.
Blood pressure measurements
Blood pressure (BP) was measured using a Mercury sphygmomanometer with proper
cuff size in standard conditions. Blood pressure measurements were carried out
according to the method recommended by the report in children (69,70). 3-5
occasional BP values were obtained and if the average of the blood pressure values
was above the 95th centile for age and sex, 24 h ambulatory blood pressure
monitoring (ABPM) was performed with a non-invasive recorder (Meditech,
Hungary) using oscillometric method. Systolic, diastolic BP and heart rate values
were also monitored with a sampling time set 20-minutes during daytime, and 30-
minutes during sleep. The duration of these periods were adjusted to the individual
timetable of the child. Those children whose mean 24h arterial blood pressure value
exceeded the 95th centile value for height and sex (71) were considered hypertensive.
(In the study of prepubertal children who were intrauterine growth retarded neonates,
there was no possibility to perform the ABPM, so we considered children to be
hypertensive when the lowest blood pressure value of the three measurements was
above the 95th centile for age and sex (72).)
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Laboratory tests
Determination of the Trp64Arg polymorphism in exon 1 of the 3-BAR gene
DNA was prepared from peripheral blood leukocytes by salting out procedure (73).
Exon 1 was amplified with polymerase chain reaction (PCR) using the primers BstN
UP: 5’-CGCCCAATACCGCCAACAG-3’ and BstN DOWN: 5’-
CCACCAGGAGTCCCATCACC-3’ (product size 210 bp).
PCR reaction was performed in a 50 μl reaction volume with 50-100 ng genomic
DNA, 10 pmol of each primer, PCR buffer containing 10 mmol/l Tris-HCL (pH 8.8),
50 mmol/l KCl, 1,5 mmol/l MgCl2, 0,1% Triton X-100, 1 U Taq polymerase, 200
μmol/l dNTP.
PCR conditions were denaturising at 94 ºC for 3 min, followed by 33 cycles of
denaturising at 94 ºC for 30 s, annealing at 64 ºC for 15 s, and extension at 72 ºC for
20 s with final extension at 72 ºC for 4 min.
Restriction enzyme analysis: 35 μl of PCR product was digested in a 50 μl volume
containing 9,1 μl deionised distilled H2O, 0,5 μl BSA (10 mg/ml), 0,4 μl enzyme
MvaI (an isoschizomer of BstNI, MBI Fermentas, 10 U/μl) and 5 μl of reaction
buffer R (MBI Fermentas) and incubated at 37 ºC for 4-18 h.
Restriction enzyme digestion products were separated on a 3% agarose gel and
visualized by staining with ethidium bromide.
Digested fragments were 97, 61, 31, 15 and 6 bp for normal homozygote; 158, 97,
61, 31, 15 and 6 bp for Trp64Arg heterozygote; and 158, 31, 15, and 6 bp for
Arg64Arg homozygote (74).
Determination of factor V Leiden mutation
The factor V Leiden mutation was tested from dried blood-spot samples according to
Zöller and Dahlbäck (75), by PCR method. The sequences of the PCR primers
(Ransom Hill Bioscience, Ramona, CA) for the amplification were the following:
forward primer: 5'GGGCTAATAGGACTACTTCTAATC3'; reverse primer:
5'TCTCTTGAAGGAAATGCCCCATTA3'. PCR amplification was carried out in a
final volume of 100 l consisting of 10 l DNA extract, 25 pmol from both primers,
200 mol/l dNTP (Pharmacia), 20 mmol/l Tris-HCL pH 8, 50 mmol/l KCl, 2.5
mmol/l MgCl2, 1.5 U Taq polymerase (Gibco or Promega). PCR conditions were 5
minutes at 94 C, followed by 30 cycles of 94 C for 40 seconds, 55 C for 1 minute
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and 72 C for 1 minute. Final extension was at 72 C for 5 minutes. The DNA was
digested by MnI restricted enzyme (Stratagene). The resulting PCR products were
separated by electrophoresis on a 2.2 % agarose gel with ethidium-bromide staining.
Biochemical studies
Plasma glucose, serum insulin and lipid levels were determined from blood samples
taken after an overnight fast in obese children. In obese children OGTT (1.75 g/kg
ideal body weight, max. 75 g) was performed. Plasma glucose and serum insulin
levels were determined at 0 and 120 min at the OGTT by the glucose oxidase method
and by commercially available radioimmunoassay (RIA) kits, respectively. C-peptide
level was also determined by RIA. The criteria of impaired glucose tolerance and
diabetes mellitus were based on the recommendation of American Diabetes
Association (76). Insulin resistance was estimated by the Homeostasis Model
Assessment (HOMA) using the formula: fasting serum insulin (IU/ml) x fasting
plasma glucose (mmol/l)/22.5 (77). (In the study of prepubertal children who were
intrauterine growth retarded neonates, the cutoff value for fasting insulin was 20
IU/ml, while hyperglycaemia was considered when the fasting blood glucose level
was more then 6.2 mmol/l.)
Serum cholesterol and triglyceride levels were determined by the enzymatic method
with Boehringer kits; serum high-density lipoprotein (HDL) cholesterol was
measured according to the method of Steele et al. (78). Serum cholesterol,
triglyceride and HDL-cholesterol were considered high or low when they fell above
or below the recommended values of the Hungarian Lipid Consensus Conference
(79): serum cholesterol > 5.2, HDL-cholesterol < 0.9 mmol/l and serum triglyceride
> 1.1 mmol/l (< 10 years)- > 1.5 mmol/l (> 10 years). If the value of any of these
parameters was abnormal, the child was considered dyslipidaemic.
Statistical analysis
All statistical analysis were performed using the Statistical Package for the Social
Sciences (SPSS) for Windows, version 7.5, 8.0 and 10.0. Data are presented as
means±SD. Statistical significance of the differences between groups was evaluated




1. Trp64Arg polymorphism of the 3-BAR gene
(8, 11, 13, 14; abstr: 2,6)*
1.1 The frequency of Trp64Arg polymorphism in normal and obese Hungarian
children was similar. The mutation occurred in 14 healthy (male: 7) and 35 obese
children (male: 23), of whom 2 were Arg64Arg homozygote and 33 were Trp64Arg
heterozygote.
1.2 The obese children with Arg64 allele were compared to a group of obese children
without it. The latter group was formed by a computer-generated randomisation. The
anthropometric data of obese children with and without polymorphism are shown in
Table 1.






Age (years) 12.3  2.9 12.6  2.9
Body height (cm) 155.7  15.9 161.4  15.4
Body weight (kg) 75.6  17.7 81.2  23.2 **
BMI (kg/m2) 30.9  3.9 35.0  10.9 ***







125.2  10.1 *
73.2  8.4
*** p < 0.05, ** p < 0.01, * p < 0.001 BMI: body mass index; BF: body fat
The weight of obese children with Arg64 allele was significantly higher (p<0.01)
than those without the polymorphism. Similar tendency (p<0.05) was observed in the
BMI and BF values. Laboratory results are shown in Table 2.
*Numbers in parenthesis are serial numbers of the papers and abstracts which were written in the issue of
the thesis.
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Plasma glucose (mmol/l) 0 min 4.40.8 4.50.9
Plasma glucose (mmol/l) 120 min 6.61.8 6.31.3
Serum insulin (IU/ml) 0 min 16.97.6 31.416.7*
Serum insulin (IU/ml) 0 min x 21.62.5 31.216.4*
Serum insulin (IU/ml) 120 min 120.071.7 101.690.2
HOMA 3.21.8 6.2 3.9*
HOMA x 3.81.3 6.1 3.8*
Serum cholesterol (mmol/l) 4.60.8 4.31.1
Serum triglyceride (mmol/l) 1.40.8 1.40.6
Serum HDL-cholesterol (mmol/l) 1.20.3 1.20.2
X adjusted for body fat, * p < 0.001 HOMA: Homeostasis Model Assessment
The serum insulin levels and HOMA were significantly higher in children carriers of
Arg64 allele as compared to those not having this. Since the two groups were
significantly different in respect of BF and BW, and these factors are closely related
to insulin levels and HOMA index, therefore these latter two parameters were
corrected for BW and BF. The corrected values remained significantly different
between the two groups. Serum triglyceride, total cholesterol and HDL-cholesterol
levels were not different between the two groups. Systolic BP of subjects with
Trp64Arg and/or Arg64Arg genotype was also significantly higher (p<0.001) than
that of those with the Trp64Trp genotype (Table 1.).
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2. Leiden mutation; size at birth and later risk factors
(3,4,5)
2.1 The prevalence of the Leiden mutation in an apparently healthy Hungarian
Caucasian population sample of our region was 6.33 % (80), which was comparable
with other European prevalence rates (81). In the group with IUGR the prevalence of
heterozygosity was not significantly different from that of the healthy Hungarian
population, while in the preterm the prevalence was 18 %. As compared to the 6.3%
prevalence rate of the healthy Hungarian population, this 18 % value of the mothers
of premature neonates proved to be significantly higher (p<0.01). The difference
between Groups PM and IUGR (18% versus 7.2%) was also significant statistically
(Table 3).























Figures in parenthesis indicate percent of total.
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2.2 According to the results cardiovascular risk factors cannot be found among
children at the age of 6-10 who were born with low birth weight (Table 4 and 5).
The anthropometric data of children are shown in Table 4.
Table 4. Anthropometric data of children at the time of examination
(prepubertal stage) (mean±SD)









1. group 2. group 3. group 4. group
Age (years) 8.81.5 8.11.5 8.71.7 9.21.6
BW (kg) 32.27.4 24.97.2* ** 28.08.6 30.19.2
BH (cm) 134.410.1 122.69.3 ** 128.29.9 130.38.3
BF (%) 22.96.8 20.55.9 20.24.4 ** 20.96.4
LBM (kg) 24.44.2 19.64.6* ** 22.26.7 ** 23.46.2
*p<0.01, ** p<0.001
BW: body weight, BH: body height, BF: body fat; LBM: lean body mass
BW: p<0.001 1. vs. 2. group; , p<0.01 2. vs. 4 group
BH: p< 0.001 1. vs. 2. 2. vs. 4 group
BF: p<0.001 1. vs. 3. group;
LBM: p< 0.001 1. vs. 2., 3. group, p<0.01 2. vs 4 group
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Weight and height of the children in the 2nd group were significantly lower than in
the 1st and 4th groups (2nd group vs. 4th group : p< 0.01; 2nd group vs. 1st group:
p<0.001). The laboratory results were normal (Table 5). Dyslipidaemia was found
21% in the 1st group, 17 % in the 2nd group, 16% in the 3rd group and 28% in
premature. There was no significant difference among the four groups. The mean of
the systolic and diastolic blood pressures were similar in the four groups.
Hypertension was detected in 12.5 % of the 1st and 3rd groups, in 5.6 % of the 2nd
group and in 8.9 % of the 4th group.
Table 5. Laboratory results of children at the time of examination
(mean±SD)









1. group 2. group 3. group 4. group
Blood glucose
(mmol/l)
4.90.8 4.60.6 4.80.8 4.60.5
Insulin
(IU/ml)
7.05.2 6.45.1 5.93.7 6.23.7
Cholesterol
(mmol/l)
4.50.8 4.30.7 4.50.6 4.40.7
HDL-chol.
(mmol/l)
1.50.3 1.60.3 1.70.4 1.60.3
Triglyceride
(mmol/l)
1.00.4 0.90.3 1.00.4 0.90.4
Systolic BP
(mmHg)
112.89.7 109.19.3 108.114.0 111.210.3
Diastolic BP
(mmHg)
66.39.7 63.08.2 62.310.3 65.19.3
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3. Impaired glucose tolerance and type 2 diabetes mellitus
(1,2,6,7,9,10,12; abstr: 1,3,4,5,7)
3.1 Because of the scarce European, especially Hungarian data of the prevalence of
T2DM our aim was to evaluate the frequency of IGT and T2DM among clinically
healthy, obese children. IGT was found in 50 children (17.3 %), while the prevalence
of T2DM was 1.7 % (n=5), so altogether the disorders of carbohydrate metabolism
could be detected in 19.0 % of the children (n=55).
The children with disturbed carbohydrate metabolism, a low calorie (1500 kcal/day),
carbohydrate (200-250 g/day) diet, and regular exercise were recommended and they
















* p < 0.001





32 children with IGT and 4 children with T2DM took part in the repeated OGTT.
Although the body weight was not changed significantly, BMI decreased
significantly (30.4±4.9 vs 29.0±4.4 kg/m2; p<0.05). The changes of mean blood
glucose and serum insulin levels are shown in Figure 1 and 2.. HOMA index also




















* p< 0.001 ** p< 0.05




DISCUSSION AND PRACTICAL CONSEQUENCES OF THE STUDIES
1. Trp64Arg polymorphism of the 3-BAR gene
According to the literature the frequency of Trp64Arg mutation of 3-BAR is highly
heterogeneous among different populations. The frequency of the mutation was
highest in the Pima Indians, followed by Japanese people and Caucasians in the USA
(15) and France (12). There was no significant difference between the frequency of
carrying the Arg64 allele of 3-BAR gene in healthy and obese Hungarian children.
The frequency was 9.5 vs. 11.8 % in the two groups, respectively, which is similar to
the frequency of this polymorphism in Europe (12,16,17). Our results are in concert
with the findings of studies conducted in children, showing a significant difference
between normal weight and obese children (16,82). Several studies have investigated
the association of Trp64Arg polymorphism of the 3-BAR gene with obesity or
weight gain, but the results are equivocal (83,84). The one possible reason for the
contradiction can be the differences in the age and extent of obesity of the subjects in
different studies. Only few studies (16,17,82) have looked at the effects of this
polymorphism on obesity and cardiovascular risk factors in children. In our present
study, the obese children with Trp64Arg and/or Arg64Arg genotypes had
significantly higher fasting serum insulin levels, HOMA indices and systolic BP
values than the Trp64Trp group. These differences remained significant when
corrected for BW and BF. The significantly higher fasting serum insulin and HOMA
values indicate the presence of insulin resistance, which together with high blood
pressure are the main features of metabolic cardiovascular syndrome. However, the
lipid levels were similar in the two obese groups. Our results are in concert with the
findings of Sakane (85) and Strazullo et al. (86).
Observations and practical consequences
The frequency of Trp64Arg polymorphism was similar in Hungary as compared to
other European countries, and there was no difference between healthy and obese
children, however the possession of Arg64 allele in obese children is associated with
higher degree of obesity, insulin resistance and hypertension, but the number of cases
need to be increased and further studies are needed to clarify these associations.
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To the best of my knowledge this is the first study of children in Hungary
investigating the frequency of a candidate gene of obesity and its effect on
cardiovascular risk factors.
Although, in the literature, there are controversial results of the role, not only, of
Trp64Arg polymorphism of 3-BAR gene, but other candidate genes, in developing
obesity, according to our findings and to know that obesity a multifactorial and
heterogeneous disorder, therefore, preventive measures for obesity, to be fully
effective in a population, must based on the modification of several potential risk
factors simultaneously. Comprehensive, successful prevention programs are needed
which should focus on promoting and supporting healthful lifestyles for all children
at home, in school and in the society. The population strategies should harmonize
lifestyle and nutritional habits with recommendations, by following the quality of
family and social nutrition for changing it, education on healthy nutrition and
physical activity. The individual level program management involves continuous
longitudinal growth and nutritional status monitoring, identification of children with
nutritive risk factors or with positive family history for obesity and for selective
screening of metabolic parameters, and healthy lifestyle and nutrition counseling.
Although the genetic analyses of the samples started at the Department of Clinical
Genetics and Child Development of University of Pécs, these investigations made
the possibility to create a scientific PCR laboratory at the Department of Paediatrics
of University of Pécs.
2. Leiden mutation; size at birth and later risk factors
As it was mentioned in the introduction, there has been considerable interest in the
possibility that prenatal events could influence the adult life. Adults who were small
at birth have been reported to have higher blood pressure and increased risk of death
from ischaemic heart disease, although there are some contradictory results.
The prevalence of Leiden mutation was 7.2% in the mothers of growth retarded
neonates and 18 % in the group of mothers of premature infants, the latter being
significantly higher than the 6.3 % prevalence of this mutation in healthy Hungarian
subjects (p<0.01). Our findings confirmed the results of Lindqvist et al (87), that the
incidence rate of activated protein C (APC) resistance of women who had IUGR
children did not differ from that in the healthy population.
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Observations and practical consequences
Our results, however, are in concert with the findings of some studies that the
presence of Factor V, Leiden mutation may have a role in premature delivery.
According to our results, cardiovascular risk factors cannot be proved among
children at the age of 6-10 who were born as intrauterine growth retarded. Further
studies are required to determine whether which stage of pregnancy might influence
birthweight and later risk factors, and it can be important at what age of children
should be examined for these risk factors.
3. Impaired glucose tolerance and type 2 diabetes mellitus
T2DM in children and adolescents is regarded as an emerging problem; however,
there are few reliable reports of its true population prevalence or its prevalence in
obese children. As the childhood population becomes increasingly overweight,
T2DM may be expected to occur in younger, prepubertal children. The young age at
presentation exposes these patients to a high risk of complications in adult life.
Observations and practical consequences
According to our prevalence data of T2DM, it seems that not it is the major problem
among obese youth, in spite of this, clinically healthy obese children have
disturbances of carbohydrate metabolism, so screening for T2DM in children and
adolescents, as suggested by the American Diabetes Association, is highly
recommended.
Impaired glucose tolerance and T2DM in asymptomatic obese children can be
managed with dietary and lifestyle interventions, resulting improvement of the
metabolic status of these children.
According to this observation and assuming that T2DM is preventable, there are two
components of the primary prevention. First of all, a populations strategy is needed,
for altering the lifestyle and the environmental determinants of T2DM. Second, a
high-risk strategy is needed for screening individuals at especially high risk for
T2DM and bringing preventive care to them.
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